These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 21142293)

  • 1. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
    Tsai D; Lipman J; Roberts JA
    Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
    Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical relevance of plasma protein binding changes.
    Roberts JA; Pea F; Lipman J
    Clin Pharmacokinet; 2013 Jan; 52(1):1-8. PubMed ID: 23150213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients.
    T'jollyn H; Vermeulen A; Van Bocxlaer J; Colin P
    Clin Pharmacokinet; 2018 Jan; 57(1):59-69. PubMed ID: 28497260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients.
    Aulin LBS; De Paepe P; Dhont E; de Jaeger A; Vande Walle J; Vandenberghe W; McWhinney BC; Ungerer JPJ; van Hasselt JGC; De Cock PAJG
    Clin Pharmacokinet; 2021 Mar; 60(3):353-363. PubMed ID: 33030704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.
    Brink AJ; Richards GA; Lautenbach EE; Rapeport N; Schillack V; van Niekerk L; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jun; 45(6):647-51. PubMed ID: 25819167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Gilder E; Kim HS; Lim SY; McGuinness S; Parke R; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA;
    Clin Pharmacokinet; 2022 Jun; 61(6):847-856. PubMed ID: 35253107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented renal clearance: implications for antibacterial dosing in the critically ill.
    Udy AA; Roberts JA; Boots RJ; Paterson DL; Lipman J
    Clin Pharmacokinet; 2010; 49(1):1-16. PubMed ID: 20000886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.
    Jager NGL; van Hest RM; Xie J; Wong G; Ulldemolins M; Brüggemann RJM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2641-2649. PubMed ID: 32443147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
    Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
    J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients.
    Boonpeng A; Jaruratanasirikul S; Jullangkoon M; Samaeng M; Wattanavijitkul T; Bhurayanontachai R; Pattharachayakul S
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084522. PubMed ID: 36226944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
    Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
    Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
    Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
    Burkhardt O; Kumar V; Katterwe D; Majcher-Peszynska J; Drewelow B; Derendorf H; Welte T
    J Antimicrob Chemother; 2007 Feb; 59(2):277-84. PubMed ID: 17185298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.